1-20 of 22
Keywords: Tamoxifen
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal: Breast Care
Breast Care (2023) 18 (4): 249–255.
Published Online: 20 April 2023
...Elif Sabancı; Melis Pehlivantürk-Kızılkan; Sinem Akgül; Orhan Derman; Nuray Kanbur Introduction: Pubertal gynecomastia is a common clinical condition among male adolescents, and in most cases, it regresses spontaneously. However, tamoxifen treatment is recommended in selected cases. We aimed...
Journal Articles
Journal Articles
Journal Articles
Journal: Breast Care
Breast Care (2021) 16 (5): 444–451.
Published Online: 15 December 2020
... breast cancer patients without adjuvant systemic therapy. In the present study we evaluated the prognostic significance of IGKC in breast cancer patients treated with adjuvant chemotherapy ± tamoxifen. Methods: IGKC expression was immunohistochemically analyzed in 193 breast cancer patients who were...
Journal Articles
Journal: Breast Care
Breast Care (2020) 15 (4): 337–346.
Published Online: 31 August 2020
...Katja Krauss; Elmar Stickeler Background: Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer. Summary: In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen...
Journal Articles
Journal: Breast Care
Breast Care (2020) 15 (2): 148–156.
Published Online: 25 July 2019
...Barbara Buonomo; Antonella Brunello; Stefania Noli; Loredana Miglietta; Lucia Del Mastro; Matteo Lambertini; Fedro Alessandro Peccatori Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use...
Journal Articles
Journal: Breast Care
Breast Care (2020) 15 (1): 72–74.
Published Online: 20 June 2019
...Hugo Herrscher; Julie Leblanc; Thierry Petit Background: The main side effects of tamoxifen are menopausal symptoms. We report a case of agranulocytosis induced by tamoxifen in a 33-year-old woman treated in the adjuvant setting. Case Presentation: Ten days after the beginning of tamoxifen...
Journal Articles
Journal Articles
Journal: Breast Care
Breast Care (2017) 12 (3): 138–144.
Published Online: 28 June 2017
... of tamoxifen or an aromatase inhibitor for all patients with HR-positive early breast cancer is considered standard; however, there are now data to support an extended approach using up to 10 years of treatment. This review will provide some historical background on endocrine therapy and summarize the key...
Journal Articles
Journal: Breast Care
Breast Care (2016) 11 (4): 240–246.
Published Online: 01 April 2016
... will alter cognitive performance. Methods: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer. Memory and spatial cognition were compared across 4 treatment groups: tamoxifen only (TAM, n = 22), aromatase inhibitor only (AI, n = 22), TAM followed by AI (‘SWITCH group', n...
Journal Articles
Journal: Breast Care
Breast Care (2015) 10 (5): 312–315.
Published Online: 11 September 2015
...Lorenzo Rossi; Olivia Pagani Summary The optimal endocrine therapy for premenopausal women with early and advanced breast cancer still remains an important and controversial issue. For over 30 years, tamoxifen has been the gold standard in the adjuvant setting. New therapeutic options...
Journal Articles
Journal: Breast Care
Breast Care (2014) 9 (6): 391–396.
Published Online: 27 November 2014
... such as tamoxifen and raloxifene (22-72%) or aromatase inhibitors (50-65%). However, the severity of side effects and the lack of evidence for an improved survival compromise the risk/benefit balance. In this review the results of chemoprevention studies, including new treatment approaches, are summarized...
Journal Articles
Journal: Breast Care
Breast Care (2014) 9 (4): 283–286.
Published Online: 14 August 2014
...Dirk O. Bauerschlag; Nicolai Maass; Christian Schem Hormone-responsive early breast cancer is a highly curable disease. In premenopausal women, tamoxifen (TAM) is still the standard treatment. Nowadays, up to 10 years of TAM can be safely administered, especially in women who remain premenopausal...
Journal Articles
Journal: Breast Care
Breast Care (2014) 9 (1): 35–39.
Published Online: 11 February 2014
...Che Lin; Li-Sheng Chen; Shou-Jen Kuo; Dar-Ren Chen Background: Currently there is a debate regarding whether tamoxifen used in breast cancer has an impact on lipid profiles. The aim of this study was to determine whether tamoxifen has an impact on the serum lipid profile in Taiwanese women...
Journal Articles
Journal: Breast Care
Breast Care (2013) 8 (6): 453–454.
Published Online: 16 December 2013
...Emre Koca; Taha Y. Kuzan; Taner Babacan; Ibrahim H. Turkbeyler; Furkan Sarici; Kadri Altundag References 1. Iguchi T, Hirokawa M, Takasugi M: Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 1986;42:1-11. 2. Tewari K...
Journal Articles
Journal: Breast Care
Breast Care (2013) 8 (2): 128–132.
Published Online: 26 April 2013
...Saadettin Kilickap; Mutlu Hayran; Banu Cakir; Nesrin Cilingiroglu; Mustafa Erman; Guldal Buyukdamgaci; Yavuz Ozisik Background: The use of endocrine therapy (ET) in postmenopausal breast cancer patients may affect their cognitive status. This study aims to assess the effects of tamoxifen...
Journal Articles
Journal Articles
Journal: Breast Care
Breast Care (2010) 5 (4): 227–232.
Published Online: 02 August 2010
...) and anti-hormonal treatment. The selection of an individual risk-adapted therapeutic approach remains controversial. This relates especially t-o the extent of surgery and the therapeutic index of adjuvant RT and tamoxifen. Several new trials have been published or updated recently that address important...
Journal Articles
Journal Articles
Journal: Breast Care
Breast Care (2008) 3 (5): 317–324.
Published Online: 21 October 2008
...Christoph Mundhenke; Christian Schem; Walter Jonat Five years of adjuvant tamoxifen treatment has been the gold standard for women with early hormone-responsive breast cancer. Results from two large phase III, adjuvant studies have indicated that the third-generation aromatase inhibitors (AIs...